Skip to content
Saturday 15 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Tuesday 14 October 2014 4:56 am  |  Updated:  Friday 07 June 2019 1:44 pm

Ebola.com on sale for $150,000 by pair who invest in disaster domain names

By: Sarah Spickernell

Add as a preferred source on Google

Business partners Jon Schultz and Chris Hood are selling Ebola.com for $150,000, after purchasing it for an undisclosed sum in 2008.
 
The Ebola outbreak currently gripping West Africa has killed over 4,000 people since it began in Guinea in February, according to estimates by the World Health Organisation (WHO). 
 
While there is currently no certified cure for the disease, a number of pharmaceutical companies, such as GlaxoSmithKline and MAPP Pharmaceutical, are trying to develop one.
 
Schultz and Hood hope that one of these companies will see the benefits of owning the domain name. In an email to CNBC, Schultz said: 
 
"Ebola.com would be a great domain for a pharmaceutical company working on a vaccine or cure, a company selling pandemic or disaster-preparedness supplies, or a medical company wishing to provide information and advertise services.
 
"There could be many other applications as well. With so many people concerned about the disease, any advertisement referring people to Ebola.com should get an excellent response."  
 
The asking price is not set in stone, however: Schultz said the domain's price "is subject to change as the situation evolves."
 
Schultz is President of the firm Blue String Ventures, which specialises in “internet real estate investment, development and brand assistance”. They are making the sale through domain name broker DigitalDNA, which has already approached a number of pharmaceutical firms to gauge their interest. 
 
It is not the first time Schultz and Hood have put their entrepreneurial spirit into practice when it comes to possible disasters – they are also the owners BirdFlu.com, Fukushima.com, and PotassiumIodide.com, among others. Potassium iodide could be used to fight diseases resulting from the radiation released in a bioterrorism or nuclear attack. 
 
Their strategy, explained Schultz, is to buy "generic domains which we think we can develop or resell later at a profit.”
 
"Having seen the movie 'Outbreak,' I was entranced by the subject and couldn't resist buying the domain,” he explained. 

 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Ebola

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • It’s not just Jason Arday, most of sociology is a scam

More from Morning Wire

  • Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

    Business Wire
  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

    Business Wire
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
  • Elliptic Announces Circle’s Participation in Agentic Design Partner Program

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Trusted Data Transfer at Mission Speed Enables Operations During UK Army’s Rhino Bizz Exercise

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook